The scale of the problem the team is attacking is enormous. Alzheimer’s disease is the most common neurodegenerative disorder in the world, and as populations age, its incidence climbs every year; by 2050, the number of people living with dementia is projected to exceed 150 million. Despite decades of effort, no drug has been found that effectively reverses the disease, largely because its pathogenesis is complex and incompletely understood and its onset unfolds over many years. The pathological picture is dominated by the abnormal accumulation of amyloid-β (Aβ42), which triggers a cascade of further damage: the aggregates provoke the overproduction of reactive oxygen species (ROS), and the resulting oxidative stress is tightly entangled with neuroinflammation, synaptic dysfunction, and progressive memory loss. Because these processes feed one another, therapies that attack only a single target have struggled. Earlier nanomaterials, including protein-capped cadmium sulfide nanoparticles and a dipeptide-modified gold nanocluster that dissolved mature amyloid fibrils, showed that inorganic agents can act on protein aggregates, but many suffered from modest inhibitory efficiency and limited dissociation ability.

Hydrogen has long been an intriguing candidate for exactly this kind of multi-target problem. The biological effects of molecular hydrogen are attributed largely to its ability to selectively scavenge highly reactive oxygen species — above all the hydroxyl radical (∙OH) — without interfering with the physiologically important ROS that cells use for signaling. Its exceptional biosafety profile has been widely confirmed, and it has been explored as a treatment for numerous inflammatory conditions. The catch is delivery. Hydrogen is poorly soluble in water and diffuses rapidly, so conventional administration routes — inhaling hydrogen gas or drinking hydrogen-rich water — cannot achieve meaningful accumulation at inflammatory sites inside the brain. Worse, any molecule hoping to reach those sites must first negotiate the blood-brain barrier, the tightly sealed endothelial boundary that restricts the entry of most drugs. The authors argue that achieving sustained, in-situ release of hydrogen at the site of neuroinflammation is therefore the crucial step for turning hydrogen therapy from a promising idea into a practical treatment for Alzheimer’s disease.

The new study’s answer is to make palladium do the work. Palladium is famous among chemists for its appetite for hydrogen: hydrogen atoms can slip into the interstitial sites of its crystal lattice, giving the metal one of the highest hydrogen storage capacities of any element, and it is highly active in catalytic hydrogenation, especially at the nanoscale. The researchers first synthesized uniform palladium nanosheets by dissolving palladium(II) acetylacetone with poly(vinylpyrrolidone) and sodium bromide in a dimethylformamide–water mixture under a carbon monoxide atmosphere at 80 °C. They then bubbled hydrogen gas through the nanoparticle solution for 15 minutes, loading the sheets to form palladium hydride. Transmission electron microscopy revealed hexagonal nanosheets roughly 37 nanometers in diameter — comfortably below the 100-nanometer threshold at which inorganic nanoparticles can efficiently penetrate a wide range of tissues, including the blood-brain barrier — with good dispersion that favors storing, transferring, and releasing hydrogen. X-ray diffraction supplied the chemical proof: compared with metallic palladium, the PdH diffraction peaks shifted slightly toward smaller angles, which, according to Bragg’s law, reflects expansion of the crystal lattice as hydrogen atoms squeeze into the interstitial sites.

The same sheets turn out to be excellent light absorbers. When aqueous PdH solutions at different concentrations were irradiated with an 808-nanometer laser at 1 watt per square centimeter for five minutes — temperature changes tracked with an infrared thermal camera — the solutions heated steeply with both time and concentration, and the material showed no obvious attenuation across three repeated heating-and-cooling cycles, a sign of excellent photothermal stability. From the fitted cooling curve, the team calculated a photothermal conversion efficiency of 38.50 percent, a competitive figure for a photothermal agent. Ultraviolet-visible-near-infrared spectroscopy showed broad absorption across the 500-to-800-nanometer range, the typical signature of palladium nanostructures, with strong absorption extending into the near-infrared. That combination of high conversion efficiency and good biocompatibility positions PdH simultaneously as a photothermal therapy agent and a photoacoustic imaging agent — the same optical property that lets the sheets heat up enough to release hydrogen and disrupt amyloid aggregates also lets them generate the acoustic waves used to visualize them inside living tissue.

Perhaps the most elegant trick is how the hydrogen gets out. Normally, detecting hydrogen in solution requires platinum nanoparticles as a catalyst; methylene blue, a redox probe, will only register hydrogen’s reducing power with platinum’s help. The PdH sheets dispense with that requirement because they act as a platinum-like autocatalyst themselves, assisting the very hydrogenation reaction that releases their own stored hydrogen. In the methylene blue assay, absorbance plummeted rapidly in the presence of PdH, while pure palladium nanoparticles left the dye essentially untouched over the same reaction period — confirming that palladium alone is not enough and that the hydrogen-loaded hydride form is what actively carries and releases hydrogen. Laser irradiation made things better still: heating the sheets under the 808-nanometer laser further enhanced their reducing power. Complementary radical-scavenging tests reinforced the antioxidant story. In the ABTS assay, the solution progressively decolorized as PdH neutralized ABTS radical cations, with absorbance at 736 nanometers falling in a concentration-dependent manner, and the DPPH assay showed the characteristic purple-to-yellow transition as radicals were quenched at 520 nanometers.

All of this activity is choreographed by imaging. Injected through the tail vein, the nanosheets generated photoacoustic signals in both the first and second near-infrared windows, with the NIR-II window offering more precise localization within the brain and strong guidance for therapy. Paired with second near-infrared fluorescence imaging using an indocyanine-green-labeled formulation, PdH-ICG, the researchers watched fluorescence develop in the brain within two hours of intravenous injection, demonstrating that the sheets readily cross the blood-brain barrier and can be used stably at their target. The authors emphasize that this is where the small size matters most: the barrier is the body’s main obstacle to treating brain disease, and inorganic nanoparticles below roughly 100 nanometers can penetrate a wide range of tissues far more easily than larger carriers. Real-time photoacoustic monitoring means the therapeutic laser is never fired blindly — the operator can first confirm that the agent has accumulated at the lesion, localize the treatment precisely, and use the same signal to evaluate the outcome.

The decisive test came in a mouse model of Alzheimer’s disease. The team injected aggregated amyloid-β 25–35 peptide — aged for seven days at 37 °C to promote fibrillization — into the right lateral ventricle of Balb/c mice via stereotaxic surgery, then split the animals into four groups: healthy wild-type controls given saline, untreated Alzheimer’s mice, mice given PdH alone, and mice given PdH followed by laser. Treated animals received intravenous PdH at 5 milligrams per kilogram every three days for four weeks; the combination group also received 808-nanometer irradiation at 1 watt per square centimeter on the skull surface for five minutes after each injection to trigger on-demand hydrogen release. In the Morris water maze — a 90-centimeter circular pool filled with water held at 24 ± 1 °C, with a 9-centimeter platform hidden one centimeter beneath the surface — all groups learned across five days of training, but the Alzheimer’s mice consistently took far longer to find the platform, and the gap with healthy controls widened as training progressed. PdH alone shortened escape latency. Most strikingly, the PdH-plus-laser group performed at a level comparable to the wild-type animals, which the authors describe as a near-complete restoration of spatial learning. In the day-six probe trial, Alzheimer’s mice swam in aimless, wall-hugging patterns, while the laser-treated mice concentrated their search in the quadrant where the platform had once been, indicating precise spatial memory.

The Y-maze test told the same story: spontaneous alternation — the tendency of a healthy rodent to explore a new arm of the maze rather than revisit the one it just left — was significantly impaired in the Alzheimer’s group compared with wild-type mice, partially rescued by PdH treatment alone, and more robustly reversed by PdH plus laser, bringing alternation percentages back to a level akin to that of normal animals. The authors trace the behavioral rescue to a set of mutually reinforcing mechanisms. The nanosheets enable sustained and light-triggered release of hydrogen, which directly scavenges cytotoxic hydroxyl radicals, easing the oxidative stress and downstream neuroinflammation that drive synaptic dysfunction and memory loss. The photothermal effect does double duty: it accelerates hydrogen release, may contribute directly to the suppression of amyloid-β aggregation, and transiently enhances blood-brain barrier permeability to improve delivery. Photoacoustic guidance keeps the entire sequence precise, ensuring the agents reach their target sites before any therapeutic light is applied.

The researchers are careful about what the results do and do not show. The model relies on injecting pre-aggregated amyloid peptide into the ventricles rather than the slow, whole-body progression of human disease, the behavioral cohorts were small, and moving the platform toward the clinic will require answers to questions the mouse study cannot address: how much near-infrared light can safely reach deep structures through a thicker human skull, how palladium behaves in the brain over months and years, and whether the transient barrier opening carries risks. Even so, the team argues that the demonstration addresses two of the field’s most stubborn challenges at once — getting an active therapy across the blood-brain barrier and intervening against multiple pathological hallmarks simultaneously — and that the approach may open a new window for treating Alzheimer’s disease. The work, funded by science and technology programs of Shanxi Province, suggests that the same logic of image-guided, hydrogen-delivering, light-activated nanomedicine could plausibly extend to other neurodegenerative conditions marked by protein aggregation and oxidative damage.

The blood–brain barrier is formed by tightly connected cells lining the brain’s blood vessels, supported by pericytes, astrocytes and specialized molecular transport systems. Its primary role is protective: it limits the entry of toxins, pathogens and many medicines from the bloodstream into neural tissue. That same selectivity, however, makes it difficult to deliver gene therapies to the brain. Injecting a treatment directly into brain tissue or the fluid surrounding the spinal cord can bypass the barrier, but those approaches are invasive and may not distribute genetic material evenly throughout the central nervous system. An intravenous treatment that could circulate through the body and selectively reach neurons would therefore represent a major advance.

AAVs are among the leading vehicles for gene therapy because they can carry genetic instructions into cells while generally producing relatively mild immune reactions compared with some other viral platforms. AAV particles consist of a protein capsid surrounding a DNA payload. The capsid determines, in part, which tissues the particle can bind to, enter and persist within. Researchers can also alter the promoter, a regulatory DNA sequence that controls when and where the delivered gene is expressed. In this study, the team examined both components together, asking not only which capsids reached the brain most efficiently, but also whether promoter choice could reduce unwanted gene activity in organs outside the nervous system.

The researchers administered the candidate vectors intravenously to mice and used reporter genes to track delivery and expression. Reporters are molecular markers that produce readily measured signals, allowing scientists to map where a vector has traveled and where its genetic cargo has become active. The experiments used the broadly active CAG promoter as well as the neuron-specific hSyn promoter. CAG is commonly used when strong expression across many cell types is desired. By contrast, hSyn is associated primarily with neuronal gene activity, making it useful for testing whether a vector that reaches multiple organs can nevertheless restrict transgene production mainly to neurons.

Compared with AAV9, the two capsids PHP.eB and CNSRCV300 showed enhanced penetration of the blood–brain barrier and stronger transduction of brain tissue. Transduction refers to the process by which a viral vector introduces genetic material into a cell and enables that material to function. The study also found that these capsids displayed a predominant neuronal tropism, meaning that their activity in the brain favored neurons over other neural or tissue cell types. This distinction matters because many neurological disorders arise from defects in neurons, although other cells—including astrocytes, oligodendrocytes and microglia—can also be important therapeutic targets. A capsid that enters the brain efficiently but reaches the wrong cell population may still be poorly suited to a particular disease.

The promoter results revealed a trade-off between potency and selectivity. Relative to CAG-driven expression, the neuron-specific hSyn promoter slightly reduced cerebral transgene expression. In other words, the brain signal was somewhat weaker when the genetic payload was placed under neuronal control rather than the more broadly active promoter. Yet hSyn markedly reduced expression in peripheral tissues. This indicates that promoter engineering can provide an additional layer of biological targeting after a vector has entered a cell. The capsid influences where the particle goes, while the promoter helps determine whether the payload is switched on in that location.

That distinction became critical when the team looked beyond reporter expression and examined the physical distribution of the vectors. Immunofluorescence, quantitative polymerase chain reaction and Western blotting all provided evidence that AAV remained in peripheral tissues, including the liver. Immunofluorescence uses labeled antibodies to visualize proteins or cellular signals in tissue sections. Quantitative PCR measures the abundance of specific DNA sequences, allowing researchers to estimate how much vector-derived genetic material is present. Western blotting detects particular proteins and can help establish whether a delivered gene is producing its intended product. Together, these tests indicated that a low level of peripheral gene expression does not necessarily mean that the viral particles themselves have been eliminated from organs outside the brain.

Among the candidates, CNSRCV300 produced what the researchers described as the most favorable balance: robust central nervous system transduction with minimal peripheral accumulation. That combination could give the capsid a stronger safety profile than vectors that reach the brain but distribute more heavily to other organs. The liver is especially important in systemic AAV therapy because intravenously delivered particles commonly pass through and accumulate there. Hepatic exposure can create safety concerns through immune responses, unintended expression, cellular stress or difficulty controlling the biological effects of the therapy. The study does not establish that CNSRCV300 is safe for human use, but it identifies a measurable design goal for future vector development: maximizing brain delivery while minimizing the amount of vector deposited elsewhere.

The findings also challenge a tempting assumption about tissue-specific promoters. A neuron-specific promoter can reduce off-target expression, but it cannot prevent a capsid from physically reaching or remaining in peripheral organs. This means safety cannot be assessed solely by measuring where the therapeutic protein is produced. Researchers must also quantify vector genomes and examine the persistence of the capsid or its genetic payload in tissues throughout the body. The authors’ conclusion is that AAV targeting is co-regulated by capsid properties and promoter characteristics, rather than controlled by either element alone. In practical terms, an effective brain-directed therapy may require coordinated optimization of the viral shell, the regulatory DNA, the therapeutic payload and the dose.

The work provides a systematic framework for screening AAV vectors intended for disorders of the central nervous system, while underscoring the gap between promising mouse data and clinical application. Biology that enables a capsid to cross the mouse blood–brain barrier may not translate directly to humans, whose vascular architecture, receptor distribution and immune responses differ. Some engineered capsids can also behave differently across species, making human-relevant testing essential. The study was performed under approved animal protocols and was supported by the Lingang Laboratory Project. Its most important message is therefore not that a universal brain-delivery vector has been found, but that future gene therapies will need to treat distribution and safety as inseparable engineering problems. Better access to the brain is valuable only when it is accompanied by precise control over where the vector travels, where the gene is expressed and how long both remain in the body.

Brain metastases occur in approximately 30% of patients suffering from these primary cancers, and despite advances in oncology, the prognosis remains grim, with median survival times falling below one year. Therapeutic options have been severely limited by the unique challenges posed by the brain’s protective barriers and microenvironment. Traditional chemotherapeutic agents and immunotherapies often fail to reach metastatic brain tumors in adequate concentrations due to the restrictive nature of the BBB. Surgical intervention is typically feasible only in select cases, further underscoring the urgent need for innovative strategies that can effectively target and eradicate brain metastases.

Addressing these challenges head-on, the researchers harnessed the natural abilities of macrophages, engineering them to express chimeric antigen receptors (CARs) specific to mesothelin, thus creating mesothelin-targeting chimeric antigen receptor macrophages (CAR-Ms). To bolster their immune efficacy and capacity for tumor cell phagocytosis, these macrophages were further fused with the MyD88 immune signaling domain, a vital adaptor molecule that amplifies inflammatory responses and pathogen defense mechanisms. This fusion gave rise to a new cellular entity described as chimeric antigen receptor macrophages fused with MyD88, or CARMA.

CARMA macrophages exhibit remarkable antitumor activity by selectively recognizing mesothelin on the surface of metastatic tumor cells in the brain. Importantly, their mode of action surpasses mere antigen-specific phagocytosis. Beyond directly engulfing and destroying tumor cells expressing mesothelin, CARMA cells secrete tumor necrosis factor (TNF), a potent cytokine that induces apoptosis in adjacent tumor cells even when they lack the targeted antigen. This dual mechanism endows CARMA with a superior ability to restrain the heterogeneous tumor populations characteristic of metastatic brain disease, addressing one of the central challenges in cancer immunotherapy.

In rigorous preclinical evaluation, CARMA demonstrated a robust capacity to penetrate the BBB—a formidable obstacle for many therapeutics—effectively reaching and infiltrating metastatic lesions within the brain parenchyma. Utilizing a humanized mouse model that closely mimics human immune responsiveness, the engineered macrophages were able to significantly curb tumor growth, exhibiting both antigen specificity and a powerful bystander effect through TNF-mediated cytotoxicity. These findings underscore the potential of macrophage-based immunotherapy in overcoming the current therapeutic inefficacies seen in brain metastases.

The novelty and success of this approach rest not only on CARMA’s ability to breach the BBB but also on the strategic enhancement of its phagocytic and immune signaling capabilities via MyD88. The MyD88 signaling module intensifies the macrophage’s immune activation state, ensuring prolonged survival, enhanced cytokine production, and a sustained cytotoxic assault on metastatic cells. This molecular synergy within CARMA empowers a level of immune orchestration and tumor targeting previously unattainable using conventional CAR-T cell therapies or unmodified macrophage approaches.

Furthermore, safety considerations, a critical aspect in immunotherapy design, have been judiciously addressed through the antigen specificity of CARMA. By targeting mesothelin—a tumor-associated antigen with limited expression in normal tissues—the therapy aims to minimize off-target effects and systemic toxicity. Also, leveraging macrophages’ natural tropism for tumors may help localize potent immunological actions within the tumor microenvironment, reducing the likelihood of systemic inflammatory responses that have complicated other immune-based therapies.

The clinical implications of CARMA therapy extend well beyond brain metastases from lung, melanoma, or breast cancers. Given macrophages’ ubiquitous presence and ease of manipulation, this platform could be adapted to target a range of other tumor-associated antigens across different malignancies with central nervous system involvement. Additionally, the modular nature of CAR engineering allows customization of immune signaling domains to optimize therapeutic profiles for various tumor types and microenvironments.

While still in preclinical stages, the success of CARMA’s design and function opens an exciting vista for future clinical trials aimed at evaluating its safety, dosing, and therapeutic efficacy in human patients. If translated successfully, CARMA could redefine standards of care for metastatic brain disease, a condition that has long been an unmet medical need due to limited and often ineffective treatment options. The potential to extend life expectancy and improve quality of life for thousands of affected patients worldwide is vast.

This innovation also revives broader discussions about the utility of innate immune cells in adoptive cell transfer therapies. Although CAR-T cell therapies have transformed certain hematological malignancies, their efficacy in solid tumors, especially within the central nervous system, remains limited. The CARMA model propels macrophages into the spotlight as versatile and potent effectors capable of overcoming anatomical and cellular hurdles that impede other immune cells.

Moreover, the inducible signaling from MyD88 within CARMA macrophages exemplifies an intelligent design approach to amplify antitumor immunity without exacerbating systemic inflammation. Leveraging innate immune pathways to coordinate targeted killing and inflammatory signaling marks a paradigm shift, integrating biological insights into the engineering of next-generation immunotherapies that are both effective and potentially safer.

The development of CARMA macrophages underscores a thoughtful and strategic convergence of cellular biology, immunology, and bioengineering aimed at resolving a critical clinical problem. It further epitomizes the potential of marrying innate immune functions with synthetic biology to craft therapeutic solutions addressing diseases located in sanctuary sites protected by formidable physiological barriers.

As the research community lauds CARMA’s preclinical accomplishments, attention now turns toward translational strategies, including scalable manufacturing processes, long-term safety profiling, and understanding interactions within the complex tumor-immune microenvironment of human patients. The implications for personalized medicine are profound, as CARMA therapies could be tailored to specific antigen profiles and disease contexts, offering bespoke immunotherapeutic regimens for individuals suffering from brain metastases and potentially other metastatic cancers.

Ultimately, the promise of CARMA may herald a new era in neuro-oncology and immunotherapy—a future where the immune system’s innate sentinels are endowed with precision-targeted weaponry, navigating the tightly regulated realms of the brain to eradicate metastatic disease and offer renewed hope to patients facing dismal prognoses.

Subject of Research:
Genetically engineered macrophages with Chimeric Antigen Receptors targeting mesothelin and fused with MyD88 signaling domain to treat metastatic brain tumors.

Article Title:
MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis.

Article References:
Wu, SY., Tyagi, A., Wu, K. et al. MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01613-x

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41551-026-01613-x